Title:
PHARMACEUTICAL COMBINATION OF ANTIBODY BINDING TO TIM-3 AND ANTIBODY BINDING TO PD-1
Document Type and Number:
WIPO Patent Application WO/2024/051670
Kind Code:
A1
Abstract:
Provided is a pharmaceutical combination of an antibody binding to TIM-3 and an antibody binding to PD-1, which comprises an anti-TIM-3 antibody or an antigen binding fragment thereof, and an anti-PD-1 antibody or an antigen binding fragment thereof; optionally, same further comprises a chemotherapeutic drug. Further provided is a kit for treating a tumor, said kit comprising the pharmaceutical combination. Additionally, further provided is a use of the pharmaceutical combination in the preparation of a drug for treating a tumor and a method for treating a tumor by the pharmaceutical combination.
More Like This:
Inventors:
GUI ZAIZHI (CN)
YU DING (CN)
WANG XUNQIANG (CN)
YUAN YANI (CN)
YU DING (CN)
WANG XUNQIANG (CN)
YUAN YANI (CN)
Application Number:
PCT/CN2023/116907
Publication Date:
March 14, 2024
Filing Date:
September 05, 2023
Export Citation:
Assignee:
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN)
International Classes:
A61K39/395; A61P35/00
Domestic Patent References:
| WO2019206095A1 | 2019-10-31 |
Foreign References:
| US20200407444A1 | 2020-12-31 | |||
| CN112566936A | 2021-03-26 | |||
| CN106977602A | 2017-07-25 |
Other References:
GIUSEPPE CURIGLIANO ET AL.: "Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 27, no. 13, 21 April 2021 (2021-04-21), pages 3620 - 3629, XP093005120, DOI: 10.1158/1078-0432.CCR-20-4746
Download PDF: